Equity Research firms currently have a positive stance on shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). The majority of analysts covering the equity have either a Buy or Strong Buy recommendation on the stock, yielding a consensus score of 2.20. This is based on the research brokerage reports taken into consideration by Thomson Reuters. Those same analysts are projecting that the stock will reach $10.89 on a short term basis.
At the time of writing, the stock was trading at $7.91. This represents a change from the opening price of -1.80%. In terms of performance, year to date, the stock is -25.49%. The monthly stock performance comes in at -2.31%. For the quarter, shares are performing at 2.16%. Weekly performance analysis shows the equity at -3.60%.
In taking a look at technical levels, shares are trading -6.34% away from the 50 day simple moving average and -4.16% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -27.81% away from it’s 52- week high and 41.92% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, Achillion Pharmaceuticals, Inc.’s RSI stands at 42.19. In looking at volatility levels, the shares saw weekly volatility of 3.53% and 4.39% over the past month.